Haemostatic Genetic Risk Factors in Arterial Thrombosis

Summary

Haemostasis plays an integral role in arterial thrombotic disease. However, establishing which of the factors are risk factors has proven surprisingly difficult. Because of its technical simplicity and digital nature, the study of haemostatic polymorphisms as risk factors has grown in popularity. Once established as a risk factor, a genetic polymorphism has the potential to aid selective prophylaxis and therapy of disease. Numerous reports have now been published on polymorphisms of coagulation and fibrinolytic factors, of coagulation and fibrinolytic inhibitory proteins, and of platelet membrane glycoprotein receptors. This article describes the polymorphisms and evaluates the results of these studies using the premises of consistency of within-report genotype/phenotype/disease relationships and consistency of outcome between studies. Many studies have been only of association between polymorphisms and disease, a type of study that is prone to error. Furthermore, the collective outcome of these studies has primarily been inconsistent. It is concluded that despite the early promise of polymorphisms as risk factors, fresh approaches differing in scale and design are now required to clarify their possible importance.

Key words

Haemostatic polymorphism - coagulation - fibrinolysis - platelet membrane glycoproteins

• References

• 1 Lane DA, Grant PJ. Role of hemostatic gene polymorphisms in venous and arterial thrombosis. Blood 2000; 95: 1517-32.
• 2 Meade TW, Mellows S, Brozovic M, Miller GJ, Chakrabarti RR, North WRS. et al. Haemostatic function and ischaemic heart disease: prinicipal results of the Northwick Park Heart Study. Lancet 1986; 2: 533-7.
• 3 Wilhelmsen L, Svardsudd K, Korsan-Bengtsen K, Larsson B, Welin L, Tibblin G. Fibrinogen as a risk factor for stroke and myocardial infarction. N Engl J Med 1984; 311: 501-5.
• 4 Heinrich J, Balleisen L, Schulte H, Assmann G, van de Loo J. Fibrinogen and Factor VII in the prediction of coronary risk. Arterioscler Thromb 1994; 14: 54-9.
• 5 Ma J, Hennekens CH, Ridker PM, Stampfer MJ. A prospective study of fibrinogen and risk of myocardial infarction in the physicians’ health study. J Amer Coll Cardiol 1999; 33: 1347-52.
• 6 Tracy RP. Epidemiological evidence for inflammation in cardiovascular disease. Thromb Haemost 1999; 82: 826-31.
• 7 Behague I, Poirier O, Nicaud V, Evans A, Arveilier D, Luc G. et al. fibrinogen gene polymorphisms are associated with plasma fibrinogen and coronary artery disease in pateints with myocardial infarction. Circulation 1996; 93: 440-9.
• 8 Humphries SE, Luong LA, Montomery HE, Day INM, Mohamed-Ali V, Yudkin JS. Gene-environment interaction in the determination of levels of plasma fibrinogen. Thromb Haemost 1999; 82: 818-25.
• 9 van’t Hooft FM, von Bahr SJF, Silveira A, Iliadou A, Eriksson P, Hamsten A. Two common, functional polymorphisms in the promoter region of the α-fibrinogen gene contribute to regulation of plasma fibrinogen concentration. Arterioscl Thromb Vasc Biol 1999; 19: 3063-70.
• 10 Lee AJ, Foekes FGR, Lowe GDO, Connor JM, Rumley A. Fibrinogen, factor VII and PAI-1 genotypes and the risk of coronary and peripheral atherosclerosis: Edinburgh artery study. Thromb Haemost 1999; 81: 553-60.
• 11 Wang XL, Wang J, McCredie RM, Wilcken DEL. Polymorphisms of factor V, factor VII, and fibrinogen genes. Relevance to severity of coronary artery disease. Arterioscler Thromb Vasc Biol 1997; 17: 246-51.
• 12 de Maat MPM, Kastelein JJP, Jukema JW, Zwinderman AH, Jansen H, Groenemeier B. et al. -455G/A polymorphism of the β-fibrinogen gene is associated with the progression of coronary atherosclerosis in symptomatic men. Proposed role for an acute phase reaction pattern of fibrinogen. Arterioscler Thromb Vasc Biol 1998; 18: 265-71.
• 13 Gardemann A, Schwartz O, Haberbosch W, Katz N, Weiss T, Tillmanns H. et al. Positive association of the β fibrinogen H1/H2 gene variation to basal fibrinogen levels and to increase in fibrinogen concentration during acute phase reaction but not to coronary artery disease and myocardial infarction. Thromb Haemost 1997; 77: 1120-6.
• 14 Tybjaerg-Hansen A, Agerholm-Larsen B, Humphries SE, Abildgaard S, Schnohr P, Nordestgaard BG. A common mutation (G-455 to A) in the β-fibrinogen promoter is an independent predictor of plasma fibrinogen, but not of ischemic heart disease. A study of 9,127 individuals based on the Copenhagen City Heart Study. J Clin Invest 1997; 99: 3034-9.
• 15 Humphries SE, Ye S, Talmud P, Bara L, Wilhelmsen L, Tiret L. European Athersclerosis Research Study: genotype at the fibrinogen locus (G_-455-A β-gene) is associated with differences in plasma fibrinogen levels in young men and women from different regions in Europe. Evidence for gender-genotype-environment interaction. Arterioscler Thromb Vasc Biol 1995; 15: 96-104.
• 16 Zito F, Di Castelnuovo A, Amore C, D’Orazio A, Donati MB, Iacoviello L. Bcl I polymorphism in the fibrinogen β-chain gene is associated with the risk of familial myocardial infarction by increasing plasma fibrinogen levels. A case-control study in a sample of GISSI-2 patients. Arterioscler Thromb Vasc Biol 1997; 17: 3489-94.
• 17 van der Bom JG, de Maat MPM, Bots ML, Haverkate F, de Jong PTVM, Hofman A, Kluft C. Elevated plasma fibrinogen. Cause or consequence of cardiovascular disease. Arterioscl Thromb Vasc Biol 1998; 18: 621-5.
• 18 Doggen CJM, Bertina RM, Manger Cats V, Rosendaal FR. Fibrinogen polymorphisms are not associated with the risk of myocardial infarction. Br J Haematol 2000; 110: 935-8.
• 19 Carter AM, Catto AJ, Bamford JM, Grant PJ. Gender-specific associations of the fibrinogen Bβ 448 polymorphism, fibrinogen levels, and acute coronary disease. Arterioscler Thromb Vasc Biol 1997; 17: 589-94.
• 20 Schmidt H, Schmidt R, Niederkorn K, Horner S, Becsagh P, Reinhart B. et al. β-fibrinogen gene polymorphism (C148 to T) is associated with carotid atherosclerosis. Arterioscler Thromb Vasc Biol 1998; 18: 487-92.
• 21 Junker R, Heinrich J, Schulte H, van der Loo J, Assman G. Coagulation factor VII and the risk of coronary heart disease in healthy men. Arterioscler Thomb Vasc Biol 1997; 17: 1539-44.
• 22 Smith FB, Lee AJ, Fowkes FGR, Price JF, Rumley A, Lowe GDO. Hemostatic factors as predictors of ischemic heart disease and stroke in the Edinburgh Artery Study. Arterioscler Thromb Vasc Biol 1997; 17: 3321-25.
• 23 Pinotti M, Toso R, Girelli D, Bindini D, Ferraresi P, Papa ML. et al. Modulation of factor VII levels by intron 7 polymorphisms: population and in vitro studies. Blood 2000; 95: 3423-8.
• 24 Hunault M, Arbini AA, Lopaciuk S, Carew JA, Bauer KA. The Arg353Gln polymorphism reduces the level of coagulation factor VII. In vivo and in vitro studies. Arterioscler Thromb Vasc Biol 1997; 17: 2825-9.
• 25 Moor E, Silveira A, van’t Hooft F, Suontaka AM, Eriksson P, Blombäck M. et al. Coagulation factor VII mass and activity in young men with myocardial infarction at a young age. Role of plasma lipoproteins and factor VII genotype. Arterioscler Thromb Vasc Biol 1995; 15: 655-64.
• 26 Lane A, Green F, Scarabin PY, Nicaud V, Bara L, Humphries S. et al. Factor VII Arg/Gln353 polymorphism determines factor VII coagulant activity in patients with myocardial infarction (MI) and control subjects in Belfast and in France but is not a strong indication of MI risk in the ECTIM study. Atherosclerosis 1996; 119: 119-27.
• 27 Heywood DM, Ossei-Gerning N, Grant PJ. Association of factor VII:C levels with environmental and genetic factors in patients with ischaemic heart disease and coronary atheroma characterised by angiography. Thromb Haemost 1996; 76: 161-5.
• 28 Iacoviello L, Di Castelnuovo A, de Knijff P, D’Orazio A, Amore C, Arboretti R. et al. Polymorphisms in the coagulation factor VII gene and the risk of myocardial infarction. N Engl J Med 1998; 338: 79-85.
• 29 Ardissino D, Mannucci PM, Merlini PA, Duca F, Fetiveau R, Tagliabue L. et al. Prothrombotic genetic risk factors in young survivors of myocardial infarction. Blood 1999; 94: 46-51.
• 30 Doggen CJM, Cats VM, Bertina RM, Reitsma PH, Vandenbroucke JP, Rosendaal FR. A genetic propensity to high factor VII is not associated with the risk of myocardial infarction in men. Thromb Haemost 1998; 80: 281-5.
• 31 Girelli D, Russo C, Ferraresi P, Olivieri O, Pinotti M, Friso S. et al. Polymorphisms in the factor VII gene and the risk of myocardial infarction in patients with coronary artery disease. N Engl J Med 2000; 343: 774-80.
• 32 Feng D, Tofler GH, Larson MG, O’Donnell CJ, Lipinska I, Schmitz C. et al. Factor VII gene polymorphism, factor VII levels, and prevalent cardiovascular disease. The Framingham Heart Study. Arterioscler Thromb Vasc Biol 2000; 50: 593-9.
• 33 Ridker PM, Hennekens CH, Lindpaintner K, Stampfer MJ, Eisenberg PR, Miletich JP. Mutation in the gene coding for coagulation factor V and the risk of myocardial infarction. N Engl J Med 1995; 332: 912-7.
• 34 Emmerich J, Poirier O, Evans A, Marques Vidal P, Arveiler D, Luc G. et al. Myocardial infarction, Arg 506 to Gln factor V mutation, and activated protein C resistance [letter]. Lancet 1995; 45: 321.
• 35 Ardissino D, Peyvandi F, Merlini PA, Colombi E, Mannucci PM. Factor V (Arg506 to Gln) mutation in young survivors of myocardial infarction. Thromb Haemost 1996; 75: 701-2.
• 36 Cushman M, Rosendaal FR, Psaty BM, Cook EF, Valliere J, Kuller LH. et al. Factor V Leiden is not a risk factor for arterial vascular disease in the elderly: results from the Cardiovascular Health Study. Thromb Haemost 1998; 79: 912-5.
• 37 Ridker PM, Hennekens CH, Miletich JP. G20210A mutation in prothrombin gene and risk of myocardial infarction, stroke, and venous thrombosis in a large cohort of US men. Circulation 1999; 99: 999-1004.
• 38 Ferraresi P, Marchetti G, Legnani C, Cavalleri E, Castoldi E, Mascoli F. et al. The heterozygous 20210 G/A prothrombin genotype is associated with early venous thrombophilias and is not increased in frequency in arterial disease. Arterioscler Thromb Vasc Biol 1997; 17: 2418-22.
• 39 Catto A, Carter A, Ireland H, Bayston TA, Philippou H, Barrett J. et al. Factor V Leiden gene mutation and thrombin generation in relation to acute stroke. Arterioscler Thromb Vasc Biol 1995; 15: 783-5.
• 40 Longstreth WT, Rosendaal FR, Siscovick DS, Vos HL, Schwartz SM, Psaty BM. et al. Risk of stroke in young women and two prothrombotic mutations: factor V Leiden and prothrombin gene variant (G20210A). Stroke 1998; 29: 577-80.
• 41 Rosendaal FR, Siscovick DS, Schwartz SM, Beverly RK, Psaty BM, Longstreth WT. et al. Factor V Leiden (resistance to activated protein C) increases the risk of myocardial infarction in young women. Blood 1997; 89: 2817-21.
• 42 Rosendaal FR, Siscovick DS, Schwartz SM, Psaty BM, Longstreth WT, Raghunathan TE. et al. A common prothrombin variant (20210 G to A) increases the risk of myocardial infarction in young women. Blood 1997; 90: 1747-50.
• 43 Doggen CJM, Cats VM, Bertina RM, Rosendaal FR. Interaction of coagulation defects and cardiovascular risk factors. Increased risk of myocardial infarction associated with factor V Leiden or prothrombin 20210A. Circulation 1998; 97: 1037-41.
• 44 Inbal A, Freimark D, Modan B, Chetrit A, Matetzky S, Rosenberg N. et al. Synergistic effects of prothrombotic polymorphisms and atherogenic factors on the risk of myocardial infarction. Blood 1999; 93: 2186-90.
• 45 Kiechl S, Muigg A, Santer P, Mitterer M, Egger G, Oberhollenzer M. et al. Poor response to activated protein C as a prominent risk predictor of advanced arterial disease. Circulation 1999; 99: 614-9.
• 46 de Stefano V, Chiusolo P, Paciaroni K, Casorelli I, Rossi E, Molinari M. et al. Prothrombin G20210A mutant genotype is a risk factor for cerebrovascular ischemic disease in young patients. Blood 1998; 91: 3562-5.
• 47 Bernardi F, Faioni EM, Castoldi E, Castaman G, Sacchi E, Mannucci PM. A factor V genetic component differing from factor V R506Q contributes to the activated protein C resistance phenotype. Blood 1997; 90: 1552-7.
• 48 Castoldi E, Rosing J, Unghi B, Hoekema L, Girelli D, Mingozzi F. et al. Factor V gene mutations (R2 gene) are associated with coronary artery disease in elderly people. Thromb Haemost. 1999 Suppl 509a (abstr).
• 49 Doggen CJM, de Visser MCH, Vos HL, Bertina RM, Manger Cats VM. et al. The HR2 haplotype of factor V is not associated with the risk of myocardial infarction. Thromb Haemost 2000; 84: 815-8.
• 50 Kohler HP, Stickland MH, Ossei-Gerning N, Carter A, Mikkola H, Grant PJ. Association of a common polymorphism in the factor XIII gene with myocardial infarction. Thromb Haemost 1998; 79: 8-13.
• 51 Wartiovaara U, Perola M, Mikkola H, Totterman K, Savolainen V, Penttila A. et al. Association of FXIII Val34Leu with decreased risk of myocardial infarction in Finnish males. Atherosclerosis 1999; 142: 295-300.
• 52 Shebuski RJ, Sitko GR, Claremon DA, Baldwin JJ, Remy DC, Stern AM. Inhibition of factor XIIIa in a canine model of coronary thrombosis: effect of reperfusion and acute reocclusion after recombinant tissue-type plasminogen activator. Blood 1990; 76: 1455-9.
• 53 Reed GL, Houng AK. The contribution of activated Factor XIII to fibrinolytic resistance in experimental pulmonary embolus. Circulation 1999; 99: 299-304.
• 54 Ariens RS, Philippou H, Nagaswami C, Weisel JW, Lane DA, Grant PJ. The factor XIII V34L polymorphism accelerates thrombin activation of factor XIII and affects cross-linked fibrin structure. Blood 2000; 96: 988-95.
• 55 Balogh I, Szôke G, Kárpáti L, Wartiovaara U, Katona E, Komáromi I. et al. Val34Leu polymorphism of plasma factor XIII: biochemistry and epidemiology in familial thrombophilia. Blood 2000; 96: 2479-86.
• 56 Catto AJ, Kohler HP, Bannan S, Stickland M, Carter A, Grant PJ. Factor XIIIVal34Leu: a novel association with primary intracerebral haemorrhage. Stroke 1998; 29: 813-6.
• 57 Elbaz A, Poirier O, Canaple S, Chédru F, Cambien F, Amarenco P. The association between the Val34Leu polymorphism in the factor XIII gene and brain infarction. Blood 2000; 95: 586-91.
• 58 Salomaa V, Matei C, Aleksic N, Sansores-Garcia L, Folsom AR, Juneja H. et al. Soluble thrombomodulin as a predictor of incident coronary heart disease and symptomless carotid artery atherosclerosis in the Atherosclerosis Risk in Communities (ARIC) Study: a case-cohort study. Lancet 1999; 353: 1729-34.
• 59 Kunz G, Ireland H, Stubbs PJ, Kahan M, Coulton GC, Lane DA. Identification and characterisation of a thrombomodulin gene mutation coding for an elongated protein with reduced expression in a kindred with myocardial infarction. Blood 2000; 95: 569-76.
• 60 Norland L, Zoller B, Ohlin AK. A novel thrombomodulin gene mutation in a patient suffering from saggital sinus thrombosis. Thromb Haemost 1997; 78: 1164-6.
• 61 Doggen CJM, Kunz G, Rosendaal FR, Lane DA, Vos HL, Stubbs PJ. et al. A mutation in the thrombomodulin gene, 127G to A coding for Ala25Thr, and the risk of myocardial infarction. Thromb Haemost 1998; 80: 743-7.
• 62 Ireland H, Kunz G, Kyriakoulis K, Stubbs PJ, Lane DA. Thrombomodulin gene mutations associated with myocardial infarction. Circulation 1997; 96: 15-8.
• 63 Norland L, Holm J, Zoller B, Ohlin AK. A common thrombomodulin amino acid dimorphism is associated with myocardial infarction. Thromb Haemost 1997; 77: 248-51.
• 64 Le Flem L, Picard V, Emmerich J, Gandrille S, Fiessinger JN, Aiach M. et al. Mutations in promoter region of thrombomodulin and venous thromboembolism. Arterioscler Thromb Vasc Biol 1999; 19: 1098-104.
• 65 Li YH, Chen JH, Wu HL, Shi GY, Huang HC, Chao TH. et al. G-33A mutation in the promoter region of thrombomodulin gene and its association with coronary artery disease and plasma soluble thrombomodulin levels. Am J Cardiol 2000; 85: 8-12.
• 66 Merati G, Biguzzi F, Oganesyan N, Fetiveau R, Qu D, Buciarelli P. et al. A 23bp insertion in the endothelial protein C receptor (EPCR) gene in patients with myocardial infarction and deep vein thrombosis. Thromb Haemost. 1999 (Supplement): 507a (abstr).
• 67 Miyata T, Sakata T, Kumeda K, Uchida K, Tsushima M, Fujimura H. et al. C-399T polymorphism in the promoter region of human tissue pathway inhibitor (TFPI) gene does not change the plasma TFPI antigen and does not cause venous thrombosis. Thromb Haemost 1998; 80: 345-6.
• 68 Moatti D, Seknadji P, Galand C, Poirier O, Fumeron F, Desprez S. et al. Polymorphisms in the tissue factor pathway inhibitor gene (TFPI) in patients with acute coronary syndromes and in healthy subjects: impact of the V264M substitution on plasma levels of TFPI. Arterioscler Thromb Vasc Biol 1999; 19: 862-9.
• 69 Moatti D, Haidar B, Fumeron F, Gauci L, Boudvillain O, Seknadji P. et al. A new T-287C polymorphism in the 5′ regulatory region of the tissue factor pathway inhibitor gene. Association studies of the T-287C and C-399T polymorphisms with coronary artery disease. Thromb Haemost 2000; 84: 244-9.
• 70 Kanaji T, Okamura T, Osaki K, Kuroiwa M, Shimoda K, Hamasaki N. et al. Common genetic polymorphism (46 C to T substitution) in the 5-untranslated region of the coagulation factor XII gene is associated with low translation efficiency and decrease in plasma factor XII level. Blood 1998; 91: 2010-4.
• 71 Zito F, Drummond F, Bujac SR, Esnouf MP, Morrissey JH, Humphries SE. et al. Epidemiological and genetic associations of activated factor XII concentration with factor VII activity, fibrinopeptide A concentration, and risk of coronary heart disease in men. Circulation 2000; 102: 2058-62.
• 72 Lupu F, Bergonzelli GE, Heim DA, Cousin E, Genton CY, Bachmann F. et al. Localization and production of plasminogen activator inhibitor-1 in human healthy and atherosclerotic arteries. Arterioscler Thromb 1993; 13: 1090-100.
• 73 Sobel BE, Woodcock-Mitchell J, Schneider DJ, Holt RE, Marutsuka K, Gold H. Increased plasminogen activator inhibitor type 1 in coronary artery atherectomy specimens from type 2 diabetic compared with non-diabetic patients A potential factor predisposing to thrombosis and its persistence. Circulation 1998; 97: 2213-21.
• 74 Kohler HP, Grant PJ. Plasminogen-activator inhibitor type 1 and coronary artery disease. N Engl J Med 2000; 342: 1792-801.
• 75 Dawson S, Hamsten A, Wiman B, Henney A, Humphries S. Genetic variation at the plasminogen activator inhibitor-1 locus is associated with altered levels of plasminogen activator inhibitor-1 activity. Arterioscler Thromb 1991; 11: 183-90.
• 76 Dawson SJ, Wiman B, Hamsten A, Green F, Humphries S, Henney AM. The two allele sequences of a common polymorphism in the promoter of the plasminogen activator inhibitor-1 (PAI-1) gene respond differently to interleukin-1 in HepG2 cells. J Biol Chem 1993; 268: 10739-45.
• 77 Gardemann A, Lohre J, Katz N, Tillmanns H, Hehrlein FW, Haberbosch W. The 4G4G genotype of the plasminogen activator inhibitor 4G/5G gene polymorphism is associated with coronary atherosclerosis in patients at high risk for this disease. Thromb Haemost 1999; 82: 1121-6.
• 78 Margaglione M, Cappucci G, Colaizzo D, Giuliani N, Vecchione G, Grandone E. et al. The PAI-1 gene locus 4G/5G polymorphism is associated with a family history of coronary artery disease. Arterioscler Thromb Vasc Biol 1998; 18: 152-6.
• 79 Eriksson P, Kallin B, van’t Hooft FM, Bavenholm P, Hamsten A. Allele-specific increase in basal transcription of the plasminogen-activator inhibitor 1 gene is associated with myocardial infarction. Proc Natl Acad Sci USA 1995; 92: 1851-5.
• 80 Ye S, Green FR, Scarabin PY, Nicaud V, Bara L, Dawson SJ. et al. The 4G/5G genetic polymorphism in the promoter of the plasminogen activator inhibitor-1 (PAI-1) gene is associated with differences in plasma PAI-1 activity but not with risk of myocardial infarction in the ECTIM study. Thromb Haemost 1995; 74: 837-41.
• 81 Ossei-Gerning N, Mansfield MW, Stickland MH, Wilson IJ, Grant PJ. Plasminogen activator inhibitor-1 (PAI-1) promoter 4G/5G genotype and levels in relation to a history of myocardial infarction in patients characterised by coronary angiography. Arterioscler Thromb Vasc Biol 1997; 17: 33-7.
• 82 Burzotta F, Di Castelnuovo A, Amore C, D’Orazio A, Di Bitondo R, Donati MB. et al. 4G/5G promoter PAI-1 gene polymorphism is associated with plasmatic PAI-1 activity in Italians: a model of gene-environment interaction. Thromb Haemost 1998; 79: 354-8.
• 83 Ridker PM, Hennekens CH, Lindpaintner K, Stampfer MJ, Miletich JP. Arterial and venous thrombosis is not associated with the 4G/5G polymorphism in the promoter of the plasminogen activator inhibitor gene in a large cohort of US men. Circulation 1997; 95: 59-62.
• 84 Doggen CJM, Bertina RM, Manger Cats V, Reitsma PH, Rosendaal FR. The 4G/5G polymorphism in the plasminogen activator inhibitor-1 gene is not associated with myocardial infarction. Thromb Haemost 1999; 82: 115-20.
• 85 Catto AJ, Carter AM, Stickland MH, Bamford JM, Davies JA, Grant PJ. Plasminogen activator inhibitor-1 4G/5G promoter polymorphism and levels in subjects with cerebrovascular disease. Thromb Haemost 1997; 77: 730-4.
• 86 Roest M, van der Sxhouw YT, Banga JD, Tempelman MJ, de Groot PG, Sixma JJ. et al. Plasminogen activator inhibitor 4G polymorphism is associated with decreased risk of cerebrovascular mortality in older women. Circulation 2000; 101: 67-70.
• 87 Ridker PM, Vaughan DE, Stampfer MJ, Manson JE, Hennekens CH. Endogenous tissue-type plasminogen activator and risk of myocardial infarction. Lancet 1993; 341: 1165-68.
• 88 Thompson SG, Kienast J, Pyke SDN, Haverkate F, van de Loo JCW. Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. N Engl J Med 1995; 332: 635-41.
• 89 Ludwig M, Wihn K-D, Scheuning W-D, Olek K. Alleleic dimorphism in the human tissue-type plasminogen activator (TPA) gene as a result of an Alu insertion/deletion event. Hum Genet 1992; 88: 388-92.
• 90 van den Eijnden-Schrauwen Y, Lakenberg N, Emeiss JJ, de Knijff P. Alu-repeat polymorphism in the tissue-type plasminogen activator gene does not affect basal endothelial tPA synthesis. Thromb Haemost 1995; 74: 1202 (letter).
• 91 van der Born JG, de Knijff P, Haverkate F, Bots ML, Meijer P, Hofman A. et al. Tissue plasminogen activator and the risk of myocardial infarction. Circulation 1997; 95: 2623-7.
• 92 Ridker PM, Baker MT, Hennekens CH, Stampfer MJ, Vaughan DE. Alu-repeat polymorphism in the gene coding for tissue-type plasminogen activator (t-PA) and risks of myocardial infarction among middle-aged men. Arterioscler Thromb Vasc Biol 1997; 17: 1687-90.
• 93 Iacoviello L, Burzotta F, Di Castelnuovo A, Zito F, Marchioli R, Donati MB. The 4G/5G polymorphism of PAI-1 promoter gene and the risk of myocardial infarction: a meta-analysis. Thromb Haemost 1998; 80: 1029-30.
• 94 Weiss EJ, Bray PF, Tayback M, Schulman SP, Kickler TS, Becker LC. et al. A polymorphism of a platelet glycoprotein receptor as an inherited risk factor for coronary thrombosis. N Engl J Med 1996; 334: 1090-4.
• 95 Carter AM, Ossei-Gerning N, Wilson IJ, Grant PJ. Association of the platelet Pl(A) polymorphism of glycoprotein IIb/IIIa and the fibrinogen B 448 polymorphism with myocardial infarction and extent of coronary artery disease. Circulation 1997; 96: 1424-31.
• 96 Ridker PM, Hennekens CH, Schmitz C, Stampfer MJ, Lindpaintner K. PlA1/A2 polymorphism of platelet glycoprotein IIIa and risks of myocar-dial infarction, stroke and venous thrombosis. Lancet 1997; 349: 385-8.
• 97 Herrmann SM, Poirier O, Marques-Vidal P, Evans A, Arveiler D, Luc G. et al. The Leu 33/Pro polymorphism (PlA1/PlA2) of the glycoprotein IIIa (GPIIIa) receptor is not related to myocardial infarction in the ECTIM Study. Thomb Haemost 1997; 77: 1179-81.
• 98 Gardemann A, Humme J, Stricker J, Nguyen QD, Katz N, Philipp M. et al. Association of the platelet glycoprotein IIIa PlA1/A2 gene polymorphism to coronary artery disease but not to nonfatal myocardial infarction in low risk patients. Thromb Haemost 1998; 80: 214-7.
• 99 Bottinger C, Kastrati A, Koch W, Mehilli J, Seidl H, Schomig K. et al. HPA-1 and HPA-3 polymorphisms of the platelet fibrinogen receptor and coronary artery disease and myocardial infarction. Thromb Haemost 2000; 83: 559-62.
• 100 Mikkelsson J, Perola M, Laipalla P, Savolainen V, Parjarinen J, Lalu K. et al. Glycoprotein IIIa PLA polymorphism associates with progression of coronary artery disease and with myocardial infarction in an autopsy series of middle-aged men who died suddenly. Arterioscler Thromb Vasc Biol 1999; 19: 2573-8.
• 101 Aleksic N, Juneja H, Folsom AR, Ahn C, Boerwinkle E, Chambless LE. et al. Platelet PLA2 allele and the incidence of coronary heart disease. Results from the Atherosclerosis Risk in the Communities (ARIC) study. Circulation 2000; 102: 1901-5.
• 102 Walter DH, Schachinger V, Elsner M, Dimmeler S, Zeiher AM. Platelet glycoprotein IIIa polymorphisms and risk of coronary stent thrombosis. Lancet 1997; 350: 1217-9.
• 103 Kastrati A, Schomig A, Seyfarth M, Koch W, Elezi S, Bottinger C. et al. PLA polymorphism of platelet glycoprotein IIIa and risk of restonosis after coronary stent placement. Circulation 1999; 99: 1005-10.
• 104 Laule M, Cascorbi I, Stangl V, Bielecke C, Wernecke KD, Mrozikiewicz P. et al. A1/A2 polymorphism of glycoprotein IIIa and association with excess procedural risk for coronary catheter interventions: a case-controlled study. Lancet 1999; 353: 708-12.
• 105 Byzova TV, Plow EF. The PLA2 allele and cardiovascular disease: the pro33 and con. J Clin Invest 2000; 105: 697-8.
• 106 Lopez JA, Ludwig EH, McCarthy BJ. Polymorphism of human glycoprotein Ib results from a variable number of tandem repeats of a 13-amino acid sequence in the mucin-like macropeptide region. J Biol Chem 1992; 267: 10055-61.
• 107 Li CQ, Garner SF, Davies J, Smethurst PA, Wardell MR, Ouwehand WH. Threonine-145/methionine-145 variants of baculovirus produced recombinant ligand binding domain of GPIbα express HPA-2 epitopes and show equal binding of von Willebrand factor. Blood 2000; 95: 205-11.
• 108 Ishida F, Furihata K, Ishida K, Yan J, Kitano K, Kiyosawa K. et al. The largest variant of platelet glycoprotein Ibα has four tandem repeats of 13 amino acids in the macroglycopeptide region and a genetic linkage with methionine. Blood 1995; 86: 1356-60.
• 109 Afshar-Kharghan V, Li CQ, Khoshnevis-Asl M, Lopez JA. Kozak sequence polymorphism of the glycoprotein (GP) Ibα gene is a major determinant of the plasma membrane levels of the platelet GP Ib-IX-V complex. Blood 1999; 94: 186-91.
• 110 Corral J, Lozano ML, Gonzalez-Conejero R, Martinez C, Iniesta JA. A common polymorphism flanking the ATG initiator codon of GPIb does not affect expression and is not a major risk factor for arterial thrombosis. Thromb Haemost 2000; 83: 23-8.
• 111 Murata M, Matsubara Y, Kawano K, Zama T, Aoki N, Yoshino H. et al. Coronary artery disease and polymorphisms in a receptor mediating shear stress-dependent platelet activation. Circulation 1997; 96: 3281-6.
• 112 Gonzalez-Conejero R, Lozano ML, Rivera J, Corral J, Iniesta JA, Moraleda JM. et al. Polymorphisms of platelet membrane glycoprotein Ib associated with arterial thrombotic disease. Blood 1998; 92: 2771-6.
• 113 Mercier B, Munier S, Bertault V, Mansourati J, Blanc JJ, Ferec C. Myocardial infarction: absence of association with VNTR polymorphism. Thromb Haemost 2000; 84: 921-2.
• 114 Reiner AP, Kumar PN, Schwartz SM, Longstreth WT, Pearce RM, Rosendaal FR. et al. Genetic variants of platelet glycoprotein receptors and the risk of stroke in young women. Stroke 2000; 31: 1628-33.
• 115 Sonoda A, Murata M, Ito D, Tanahshi N, Ohta A, Tada Y. et al. Association between platelet glycoprotein Ib genotype and ischemic cerebrovascular disease. Stroke 2000; 31: 493-7.
• 116 Kunicki TJ, Orchekowski R, Annis D, Honda Y. Variability of integrin α2β1 activity on human platelets. Blood 1993; 82: 2693-703.
• 117 Kuniki TJ, Orchekowski R, Annis D, Nugent DJ. Hereditary variation in platelet α2β1 density is associated with two silent polymorphisms. Blood 1997; 89: 1939-43.
• 118 Di Paola J, Federici AB, Mannucci PM, Canciani MT, Kritzik M, Kunicki TJ. et al. Low platelet α2β1 levels in type I von Willebrand disease correlate with impaired platelet function in a high shear stress system. Blood 1999; 93: 3578-82.
• 119 Santoso S, Kalb R, Kiefel V, Mueller-Eckhardt C, Newman PJ. The human platelet alloantigens Bra and Brb are associated with a single amino acid polymorphism on glycoprotein Ia (integrin α2 subunit). J Clin Invest 1993; 92: 2427-32.
• 120 Santoso S, Kunicki TJ, Kroll H, Haberbosch W, Gardemann A. Association of the platelet glycoprotein Ia C807T gene polymorphism with nonfatal myocardial infarction in younger patients. Blood 1999; 93: 2449-53.
• 121 Moshfegh K, Wuillemin WA, Redondo M, Lammle B, Beer JH, LiechtiGallati S. et al. Association of two silent polymorphisms of the platelet glycoprotein Ia/IIa receptor with risk of myocardial infarction: a case control study. Lancet 1999; 353: 351-4.
• 122 Croft SA, Hampton KK, Sorrell JA, Steeds RP, Channer KS, Samani NJ. et al. The GPIa C807T dimorphism associated with platelet collagen receptor density is not a risk factor for myocardial infarction. Br J Haematol 1999; 106: 771-6.
• 123 Kroll H, Gardemann A, Fechter A, Haberbosch W, Santoso S. The impact of the glycoprotein Ia collagen receptor subunit A1648G gene polymorphism on coroanry artery disease and acute myocardial infarction. Thromb Haemost 2000; 83: 392-6.
• 124 Roest M, Banga JD, Grobbee DE, de Groot PG, Sixma JJ, Tempelman MJ. et al. Homozygosity for 807 T polymorphism in α2 subunit of platelet α2β1 is associated with increased risk of cardiovascular mortality in high-risk women. Circulation 2000; 102: 1645-50.
• 125 von Beckerath N, Koch W, Mehilli J, Bottinger C, Schomig A, Kastrati A. Glycoprotein Ia gene C807T polymorphism and risk for major adverse cardiac events within the first 30 days after coronary artery stenting. Blood 2000; 95: 3297-301.
• 126 Meisel C, Cascorbi I, Herrmann A, Roots I, Laule M, Stangl V. et al. The platelet glycoprotein Ia C807T polymorphism as risk factor for coronary catheter interventions. Blood 2000; 96: 2002-3.
• 127 Carlsson LE, Santoso S, Spitzer C, Kessler C, Greinacher A. The α2 gene coding sequence T807/A873 of the platelet collagen receptor integrin α2β1 might be a genetic risk factor for the development of stroke in younger patients. Blood 1999; 93: 3583-6.
• 128 Collins FS. Shattuck Lecture-medical and societal consequences of the human genome project. N Engl J Med 1999; 341: 28-37.